This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Alzheimer's Disease or Mild Cognitive Impairment
and you are
over 45
years old
The phase for this study is not defined.
Show me locations

The purpose

The aim of this study is to examine the relationship between plasma putative biomarkers for Alzheimer's disease (i.e. Ab40 amyloid and total Ab42 amyloid, free, bound, free/bound, truncated, sAPPα) and : - the risk of conversion of individuals with Mild Cognitive Impairment (MCI) into Alzheimer's disease (AD), - the Alzheimer's disease progression rate.

Provided treatments

  • Biological: biomarkers, MRI and CSF

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01315639. The sponsor of the trial is Assistance Publique Hôpitaux de Paris and it is looking for 1067 volunteers for the current phase.
Official trial title:
Plasma Abeta Peptides and the Risk of Alzheimer's Disease. Diagnostic Performance and Predictive and Prognostic Values of Measurements of Plasma Amyloid Peptides Concentrations for the Diagnosis of Alzheimer's Disease